Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: HCM
Latest Price: 425.00p  (-2.86% Descending)
52-week High: 535.00p
52-week Low: 172.00p
Market Cap: 220.13M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Hutchison China MediTech Limited
www.chi-med.com/eng/global/home.php
Hutchison China MediTech Limited (Chi-Med) is the holding company of a pharmaceutical and healthcare group, which is engaged in the research, development, manufacture and sale of pharmaceuticals, health supplements and other consumer health and personal care products derived from traditional Chinese medicine (TCM) and botanical ingredients. The Company operates in three main areas: China healthcare, which comprises the development, manufacture, distribution and sale of TCM pharmaceuticals and health supplements; consumer products business, which relates to TCM-based consumer products sold through retail stores, and drug research and development, which relates mainly to pharmaceutical research and development. The Company is developing Sen as a TCM consumer brand in TCM medicines and treatments, food and beverage, and skin and body care products through its own network of retail stores.
Full Hutchison China MediTech Limited profile here
Pdf

Hutchison China MediTech forms JV with Hain Celestian to market toddler feeding products

8th Oct 2009, 5:18 am Hutchison China MediTech forms JV with Hain Celestian to market toddler feeding products

Hutchison Whampoa’s subsidiary Hutchison China MediTech Limited (Chi-Med; AIM: HCM) said today its wholly owned subsidiary Hutchison Organic Holdings Limited entered into a joint venture (JV) agreement with The Hain Celestial Group (NASDAQ: HAIN) to market and distribute infant and toddler feeding products in China and other markets.


Each partner will hold 50% in the JV called Hutchison Hain Organic Holdings Limited. The products will be co-branded under the Earth-s Best and Zhi Ling Tong brand names as well as selected Hain Celestial brands.

“Tapping into Hain Celestial's know-how in natural and organic infant feeding is an important step forward in Chi-Med's strategy. The joint venture leverages Chi-Med's extensive China distribution network and significantly adds to our platform in infant nutrition, one of China's fastest growing categories. It also capitalises on the long-established relationships and international retail strengths of Hutchison Whampoa to grow Hain Celestial's portfolio of brands in the region, to our mutual benefit,” said Chief Executive of Chi Med Christian Hogg.


Chi-Med rallied 10% in early trade following the release of the announcement.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.